Literature DB >> 10593603

Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter.

K G Lambe1, N J Woodyatt, N Macdonald, S Chevalier, R A Roberts.   

Abstract

In rats and mice, peroxisome proliferators (PP) cause liver enlargement, hepatocarcinogenesis and peroxisome proliferation associated with induction of enzymes such as acyl CoA oxidase (ACO). However, humans appear to be non-responsive to the adverse effects of PPs such as ACO induction. PPs activate the peroxisome proliferator activated receptor alpha (PPARalpha) that binds to DNA at peroxisome proliferator response elements (PPREs) within the promoters of PP-responsive genes. When the human ACO promoter was cloned previously (Varanasi et al., 1996. Journal of Biological Chemistry, 271, 2147-2155), it was reported to contain a PPRE (5' AGGTCA C TGGTCA 3') that bound PPARalpha and could be activated in vitro by Wyeth-14,643 (at >1 mM) or DEHP (at > 1.5 mM). In contrast, when we cloned the ACO gene promoter from a human liver biopsy, it was non-responsive to PPs and differed at three positions (5' AGGTCA G CTGTCA 3') from that reported previously (Woodyatt et al., 1999. Carcinogenesis, 20, 369-375). Subsequent to this, Varanasi et al. re-sequenced their constructs and obtained the same sequence as we have described (Varanasi et al., 1998. Journal of Biological Chemistry, 273, 30832). However, the observation that the errant sequence (5' AGGTCA C TGGTCA 3') was able to bind PPARalpha still remained since it appears that this sequence was used by Varanasi et al. (1996) to design oligonucleotides for their DNA binding analyses. Thus, if the 5' AGGTCA C TGGTCA 3' sequence did exist in some individuals, it could be active. To address this, we used site-directed mutagenesis to create a promoter fragment that contained the errant sequence. This reporter gene was transfected into NIH3T3 cells together with a plasmid expressing mPPARalpha, and assessed for its ability to drive PP-mediated gene transcription using a non-toxic concentration of Wyeth-14,643 (100 microM). This human ACO promoter was also inactive, unlike the equivalent rat ACO promoter fragment used as a positive control. Next, we used site directed mutagenesis to convert the PPRE found in the active rat ACO promoter (3' AGGACA A AGGTCA 5') to our inactive human sequence (AGGTCA G CTGTCA). This human PPRE was unable to drive PP-induced gene transcription even in the context of the rat ACO promoter suggesting that the activity of the rat promoter is conferred principally by the PPRE sequence, even though it may be enhanced by flanking sequences. These data confirm that neither the native nor the errant human ACO gene PPRE can respond to PPs. The absence of a responsive PPRE contributes to our understanding of the lack of response of humans to some of the adverse effects of the PP class of non-genotoxic hepatocarcinogens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593603     DOI: 10.1016/s0378-4274(99)00151-4

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  10 in total

1.  Peroxisome proliferators and peroxisome proliferator-activated receptor alpha: biotic and xenobiotic sensing.

Authors:  Janardan K Reddy
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

2.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Kevin M Korenblat; Faidon Magkos; Jennifer McCrea; Bruce W Patterson; Samuel Klein
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

Review 3.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

Review 4.  The role of fibric acids in atherosclerosis.

Authors:  J C Fruchart; B Staels; P Duriez
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

Review 5.  Interactions between nuclear receptors glucocorticoid receptor α and peroxisome proliferator-activated receptor α form a negative feedback loop.

Authors:  Hongjiao Gao; Yujue Li; Xiang Chen
Journal:  Rev Endocr Metab Disord       Date:  2022-04-27       Impact factor: 9.306

6.  Role of peroxisome proliferator-activated receptor-α on the synthesis of monounsaturated fatty acids in goat mammary epithelial cells.

Authors:  Huibin Tian; Jun Luo; Hengbo Shi; Xiaoying Chen; Jiao Wu; Yusheng Liang; Cong Li; Juan J Loor
Journal:  J Anim Sci       Date:  2020-03-01       Impact factor: 3.159

Review 7.  Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

Authors:  Eric R Kallwitz; Alan McLachlan; Scott J Cotler
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

8.  Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.

Authors:  Youcai Zhang; Andrew J Lickteig; Iván L Csanaky; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2017-12-01       Impact factor: 4.849

9.  The Role of PPARs in Cancer.

Authors:  Keisuke Tachibana; Daisuke Yamasaki; Kenji Ishimoto; Takefumi Doi
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 10.  Integrated physiology and systems biology of PPARα.

Authors:  Sander Kersten
Journal:  Mol Metab       Date:  2014-03-06       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.